share_log

瑞银:上调威高股份目标价至7.4港元 续列为医疗科技板块首选股之一

UBS Group: Raised the Target Price for WEIGAO GROUP to HKD 7.4, continuing to rank as one of the preferred stocks in the Medical Technology Sector.

Breakings ·  Mar 27 06:29

UBS Group published a research report indicating that WEIGAO GROUP's revenue last year fell by 1.1% year-on-year to 13.09 billion yuan, lower than the bank's and market expectations. Net profit rose by 3.2% year-on-year to 2.07 billion yuan, exceeding the bank's expectations but falling short of market expectations. The group provided a revenue growth guidance of 10% to 15% for this year, with a projected dividend payout ratio of 50% this year. The bank believes that despite the seemingly optimistic revenue forecast for this year, significant improvements in shareholder returns will become a key catalyst for driving up the stock price. The bank has lowered its revenue forecasts for this year and next, while raising the earnings per share estimates for each year by 2% and lowering them by 1%, respectively, and also raised the annual dividend payout ratio forecast within the company's predictions to 50%. The bank indicated that the Target Price has been raised from HKD 7 to HKD 7.4, continuing to rank as one of the preferred stocks in China's Medical Technology Sector, and reaffirmed its rating of 'Buy'.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 259

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.